Report LibraryAll Reports
Breast Cancer KOL Interview – UK
July 18, 2022
A UK-based key opinion leader (KOL) provides insights into prescribing habits, key marketed brands, and late-phase pipeline therapies across all three subtypes of breast cancer. Key pipeline assets highlighted include Enhertu, Trodelvy, Tecentriq, and enobosarm.
If you are a KOL Insight Subscriber, please access the interview from our KOL Insight portal (Subscribers only).
Biomedtracker will be offering KOL Reports and Physician Pulse Surveys for purchase a la carte, or access to all reports and surveys can be purchased as a subscription to KOL Insight. For more information on KOL Insight subscription, please email Biomedtracker or call Biomedtracker Client Services at (858) 200-2357.
For our disclosures, please read the Biomedtracker Research Standards.
|Indications Covered:||Breast Cancer|
- Breast Cancer KOL Interview – US, Midwest
- Breast Cancer KOL Interview – US, Northeast
- Datamonitor Healthcare Oncology Disease Analysis: HER2+ Breast Cancer
- Datamonitor Healthcare Oncology Disease Analysis: HR+/HER2- Breast Cancer
- Datamonitor Healthcare Oncology Disease Analysis: Triple-Negative Breast Cancer